Evidence map›Paper›PMID 36319039›Full record

ArticleBMJ case reports2022

Gemcitabine-induced digital ischaemia in a patient with metastatic breast cancer.

Abdul Moiz Khan, Lubina Arjyal, Lelas Shamaileh, Michael Simon

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Abdul Moiz KhanHematology and Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA.ORCID http://orcid.org/0000-0002-0724-0766
Lubina ArjyalHematology and Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA.
Lelas ShamailehHematology and Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA.
Michael SimonHematology and Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA simonm@karmanos.org.
The Barbara Ann Karmanos Cancer Institute · USWayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A woman in her 50s with HER2 (human epidermal growth factor receptor 2) positive, estrogen/progesterone receptor negative, metastatic invasive ductal carcinoma of the breast, presented with acral cyanosis and severe throbbing pain after recent administration of gemcitabine. She was treated with aspirin, heparin, amlodipine, topical nitroglycerin and analgesics. Gemcitabine was discontinued permanently. She had a gradual recovery except for a small necrotic area over the right 4th digit. However, surgical intervention was avoided.

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastDeoxycytidineFemaleGemcitabineHumansIschemiaMiddle AgedDeoxycytidineGemcitabineBreast cancerSafetyUnwanted effects / adverse reactionsVasculitis

Identifiers

PMID36319039
PMCPMC9628528
OpenAlexW4308015502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.